Education
About Us
Working with TipRanks
Follow Us
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. (DE:6NQ)
:6NQ
Total Valuation
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. has a market cap or net worth of €71.27M. The enterprise value is ―.
Market Cap€71.27M
Enterprise Value―
Share Statistics
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. has 70,770,580 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding70,770,580
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 3.54%.
Return on Equity (ROE)0.06
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)3.54%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee300.23K
Profits Per Employee31.59K
Employee Count239
Asset Turnover0.24
Inventory Turnover2.83
Valuation Ratios
The current PE Ratio of Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. is 41.3. Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.’s PEG ratio is ―.
PE Ratio41.3
PS Ratio0.00
PB Ratio0.00
Price to Fair Value2.62
Price to FCF0.00
Price to Operating Cash Flow18.44
PEG Ratio―
Income Statement
In the last 12 months, Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. had revenue of 71.76M and earned 7.55M in profits. Earnings per share was 0.11.
Revenue71.76M
Gross Profit44.25M
Operating Income12.43M
Pretax Income9.64M
Net Income7.55M
EBITDA12.75M
Earnings Per Share (EPS)0.11
Cash Flow
In the last 12 months, operating cash flow was 18.42M and capital expenditures -30.11M, giving a free cash flow of -11.69M billion.
Operating Cash Flow18.42M
Free Cash Flow-11.69M
Free Cash Flow per Share-0.17
Dividends & Yields
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.32
52-Week Price Change9.89%
50-Day Moving Average1.11
200-Day Moving Average1.08
Relative Strength Index (RSI)45.34
Average Volume (3m)0.00
Important Dates
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. as a current ratio of 1.07, with Debt / Equity ratio of 62.71%
Current Ratio1.07
Quick Ratio0.85
Debt to Market Cap0.24
Net Debt to EBITDA6.25
Interest Coverage Ratio4.00
Taxes
In the past 12 months, Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. has paid 2.09M in taxes.
Income Tax2.09M
Effective Tax Rate0.22
Enterprise Valuation
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. EV to EBITDA ratio is 31.25, with an EV/FCF ratio of -14.17.
EV to Sales5.55
EV to EBITDA31.25
EV to Free Cash Flow-14.17
EV to Operating Cash Flow29.02
Balance Sheet
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. has €3.00K in cash and marketable securities with €75.84M in debt, giving a net cash position of -€75.83M billion.
Cash & Marketable Securities€3.00K
Total Debt€75.84M
Net Cash-€75.83M
Net Cash Per Share-€1.07
Tangible Book Value Per Share€1.70
Margins
Gross margin is 63.16%, with operating margin of 17.32%, and net profit margin of 10.52%.
Gross Margin63.16%
Operating Margin17.32%
Pretax Margin13.44%
Net Profit Margin10.52%
EBITDA Margin17.76%
EBIT Margin17.76%
Analyst Forecast
The average price target for Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―